CONSTANT LEVERAGE LONG - ELI LILLY & CO | Real-time Euronext Paris 09:53:53 2024-05-22 am EDT | ||
| 9.165 EUR | -3.78% |
|
| Current month | +6.19% | ||
| 1 month | +56.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 9.165 | -3.78% |
| 24-05-21 | 9.525 | +24.75% |
| 24-05-20 | 7.635 | +10.89% |
| 24-05-17 | 6.885 | -7.83% |
| 24-05-16 | 7.47 | -3.11% |
Real-time Euronext Paris
Last update May 22, 2024 at 09:53 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| XL5NB | |
| ISIN | NLBNPNL2OS26 |
| Date issued | 2024-03-13 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.02 € |
|---|---|
| Lowest since issue | 5.06 € |
| Spread | 0.93 € |
| Spread % | 8.99% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- XL5NB Certificat
